Engineered immune cells take on stomach cancer in new trial
NCT ID NCT07538856
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new treatment called CT0494BCP CAR-T cells in 50 adults with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to see if the treatment is safe and to get an early look at whether it can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BeijingGoBroadH
Beijing, Beijing Municipality, 10000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a double immunotherapy beat standard care for a tough stomach cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- New Dual-Action antibody could extend lives in stomach cancer
- Stomach cancer study may spare some patients unnecessary surgery
- New cancer drug ALK-N001 enters early human testing
- Blood test could spare stomach cancer patients from unnecessary chemo